Journal of Substance Use
October 3, 2026
Philip George Harris
Background Ketamine use has increased in recent years, with growing recognition of associated physical, psychological, and cognitive harms. Existing assessment approaches, largely derived from dependence-based models, may be insufficiently sensitive to the multi-domain and progressive nature of ketamine-related harm, particularly in its earlier stages.Methods A vignette-based inter-rater...
Pharmacopsychiatry
October 2, 2026
Masami Murao, Daiki Setoyama, Yasuyuki Matsumoto et al.
Abstract This study investigated the antisuicidal effects of repeated intravenous ketamine in patients with treatment-resistant depression and explored associations between suicidal ideation and temporal changes in selected plasma biomarkers to identify potential biomarkers. This secondary analysis of an open-label trial included outpatients with treatment-resistant depression who received four...
Neuropsychiatric Disease and Treatment
October 1, 2026
Anita Słupska, Wiesław Jerzy Cubała, Damian Swieczkowski et al.
Objective: To synthesize evidence for intravenous racemic ketamine and regulated intranasal esketamine in adults with acute suicidal presentations; distinguish the outcomes these interventions have and have not been shown to change; and place any rapid response within a complete emergency suicide-care pathway. Methods: A narrative review of PubMed/MEDLINE-indexed literature was updated through...
International Journal of Pharmaceutical and Clinical Research
October 1, 2026
H Gayathri, J Nivedhya, K Purushothama Reddy et al.
Aim: To assess the effectiveness of ketamine-based treatment for adults with treatment-resistant depression in terms of the persistence of antidepressant responses or remission after treatment discontinuation. Data Sources: PubMed/MEDLINE database search was performed to select randomized clinical trials that assessed the effect of ketamine interventions on TRD in adults. Study Selection: The...
Psychedelics
October 1, 2026
David S. Mathai, Brian Pilecki, Hadi Zaki et al.
In 2019, the U.S. Food and Drug Administration (FDA) approved a patented formulation and delivery method of esketamine, the S-enantiomer of ketamine, for patients with treatment-resistant depression (TRD). While ketamine-based treatments share similarities with serotonin 2 A receptor-mediated “classic psychedelics” like psilocybin regarding subjective drug effects and stimulation of...
Pain Management
October 1, 2026
Steven Paul Cohen, Roman Smolynets, Jordan Wood et al.
BACKGROUND: Posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI) are conditions that share common mechanisms and are highly co-prevalent with each other and chronic pain. This pragmatic study will compare ketamine infusions to stellate ganglion blocks (SGB), their combination, and a placebo-sham-controlled arm. METHODS: A double-blind study conducted at 3 U.S. and Ukrainian...
Frontiers in Psychiatry
October 1, 2026
Matthew M. Kinney, Zackary L. Bowers
Ketamine has progressed from solely being an anesthetic agent to a drug of rising clinical and research interest due to its distinctive pharmacological properties. Its dissociative properties and rapid-acting antidepressant effects have made it a prominent area of investigation across many medical and psychiatric applications. This systematic review examines ketamine’s history, mechanisms of...
Research Square
September 30, 2026
Merve Mollaahmetoglu, Joy Krecké, Charlie Oldfield et al.
preprint
Abstract Ketamine is known to have anti-depressant effects and is suggested to reduce substance use. However, little is known about the mechanism of these effects. Given evidence from studies in depression of a greater therapeutic effect in those with a family history of AUD, this latter factor was also investigated as a moderating factor. We used data from the KARE trial, a randomised...
September 29, 2026
Paul S. Links
Consider neuromodulation for BPD patients with comorbid major depression who have failed antidepressants and other medications. Systematic review evidence supports a supplementary role in these cases. When using ketamine in BPD, monitor carefully for disinhibited behaviors and increased suicidal ideation. Case reports have documented both as negative reactions. MDMA-assisted psychotherapy has...
September 29, 2026
Paul S. Links
Overweeg neuromodulatie voor patiënten met borderline persoonlijkheidsstoornis en comorbide majeure depressie bij wie antidepressiva en andere medicatie hebben gefaald. Systematische review-evidentie ondersteunt een aanvullende rol in deze gevallen. Let bij het gebruik van ketamine bij borderline persoonlijkheidsstoornis goed op ontremd gedrag en toegenomen suïcidale ideatie. Casusrapporten...